Expired Canadian patentCanada
Use of hpv-16 e6 and e7-gene derived peptides for the diagnostic purpose
CA 2073616 C · Owner: Behring Diagnostics Gmbh · Inventors: Mueller, Martin; Gissmann, Lutz
Overview
Drawings and full text
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to the use of human paillomavirus 16 (HPV-16) E7-gene derived peptides fot the diagnostic identification of HPV-16-associated invasive cervical cancer.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 10, 1992 and granted November 4, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 10, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 10, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledJuly 10, 1992
GrantedNovember 4, 2003
Term endedJuly 10, 2012
Patent numberCA 2073616 C
Classification (IPC)C07K16/08 +2 more
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.